You are here:
| Reference : Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal ad... |
| Scientific journals : Article | |||
| Life sciences : Veterinary medicine & animal health Human health sciences : Immunology & infectious disease Human health sciences : Laboratory medicine & medical technology | |||
| http://hdl.handle.net/2268/7678 | |||
| Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD | |
| English | |
| Gogev, S. [> > > >] | |
| Vanderheijden, N. [> > > >] | |
| Lemaire, Mylène [ > > ] | |
| Schynts, F. [> > > >] | |
| D'Offay, J. [> > > >] | |
| Deprez, I. [> > > >] | |
| Adam, Martine [Centre Hospitalier Universitaire de Liège - CHU > > Ophtalmologie >] | |
| Eloit, M. [> > > >] | |
Thiry, Etienne  [Université de Liège - ULg > Département des maladies infectieuses et parasitaires > Virologie, épidémiologie et pathologie des maladies virales >] | |
| 31-Jan-2002 | |
| Vaccine | |
| Elsevier Sci Ltd | |
| 20 | |
| 9-10 | |
| 1451-1465 | |
| International | |
| 0264-410X | |
| Oxford | |
| [en] BHV-1 ; glycoprotein D ; recombinant human adenovirus type 5 | |
| [en] Replication-defective human adenoviruses type 5 (HAd5) expressing the bovine herpesvirus type 1 (BHV-1) glycoprotein gC or gD under the control of the human cytomegalovirus immediate-early promoter/enhancer (AdCMVgC or AdCMVgD) or the 5' regulatory region of the human desmin gene (AdDESMgC or AdDESMgD) were generated. A preliminary experiment performed on rabbits showed that the intranasal administration of AdCMV elicited higher levels of BHV-1 neutralizing antibodies than the intramuscular administration of AdDESM. The obtained results allowed to select the replication-defective AdCMVgC and AdCMVgD for further assessment of their potential as a recombinant vaccine in cattle. Calves were injected intranasally twice 3 weeks apart with either AdCMVgC or AdCMVgD or a combination of these two recombinants or a commercially available live vaccine for comparison. The highest BHV-1 neutralizing antibody titres were obtained with AdCMVgD followed by the live vaccine and to a lower extent with the combination of the two recombinants (AdCMVgC+AdCMVgD). Calves were protected against intranasal BHV-1 challenge performed 3 weeks after the second immunization. In view of the obtained results, recombinant HAd5 may be developed as an intranasal vaccine vector in cattle administrated either alone or sequentially with non-human adenovirus-based vectors. | |
| http://hdl.handle.net/2268/7678 |
| File(s) associated to this reference | ||||||||||||||
|
Fulltext file(s):
| ||||||||||||||
All documents in ORBi are protected by a user license.
